Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024
Experts in lower-risk myelodysplastic syndromes analyze and interpret the comparative biomarker data on ring sideroblasts in LR-MDS patients from the COMMANDS study.
Read More
Treatment Decision-Making Based on the COMMANDS Trials
The panel examines the COMMANDS trial results, focusing on luspatercept's effects across erythroid, neutrophil, and platelet lineages and their implications for treatment decisions, while also exploring how genomic factors and mutational burden influence the drug's clinical outcomes in lower-risk myelodysplastic syndromes.
Read More
Clinical Implications of COMMANDS Trial in Clinical Practice
The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.
Read More
Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial
A key opinion leader offers insights and analysis on the recently presented COMMANDS trial data from the European Hematology Association 2024 conference.
Read More
The experts examine the COMMANDS trial, which assessed luspatercept in lower-risk myelodysplastic syndrome patients, detailing the trial's design, participant groups, and key outcome measures.
Read More
Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies
The experts describe their strategies for selecting first-line treatments in lower-risk myelodysplastic syndrome patients, focusing on the key factors that inform their sequencing decisions in frontline therapy.
Read More
Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS
Key opinion leaders address various challenges linked to lower-risk myelodysplastic syndromes, with a focus on cytopenias.
Read More
The expert panel in hematology examines recent WHO and ICC guideline updates, evaluating their impact on the evolving treatment landscape for myelodysplastic syndromes.
Read More
Amer Zeidan, MBBS, MHS, presents data from the IMerge phase 3 study on the efficacy of imetelstat in achieving red blood cell transfusion independence across different risk subgroups in patients with lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis-stimulating agents.
Read More